Is Cervarix building up a cause for the NIP?
The company which owns ‘Cervarix,’ a uterine cervix cancer vaccine, announced data of an cost-benefit analysis that the drug is more cost-effective than its competing product, ‘Gardasil.’ In the circumstance where it has governmental bidding ahead as the drug was selected as the next year’s vacci...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
